
ICON Public Limited Company ICLR
$ 176.57
-3.31%
Annual report 2024
added 01-10-2026
ICON Public Limited Company Accounts Payables 2011-2026 | ICLR
Accounts payable — are the obligations of an organization to other legal entities or individuals that arise in cases when the company has acquired goods or services on deferred payment terms, has not paid taxes and fees, has wage arrears to employees, or has received loans and other liabilities. Accounts payable arise when an organization has already received some benefit but has not yet paid for it.Main types of accounts payable
| Type of liability | Example |
|---|---|
| To suppliers and contractors | Goods received but not yet paid for |
| Taxes and fees | VAT, income tax, etc., not paid on time |
| Salaries | Employee wages not paid |
| To budgets | Insurance contributions to funds not paid |
| To founders | Founders provided borrowed funds |
| To banks | Overdue loan payments |
| Other | Fines, penalties, forfeits, customer prepayments, etc. |
Impact on the company's financial performance
- Liquidity and solvency
Accounts payable are part of short-term liabilities, so they affect liquidity ratios - Financial stability
The higher the share of borrowed funds (including accounts payable), the lower the company's level of independence - Capital turnover
Moderate accounts payable can positively affect working capital by allowing the company to use “free” financing from suppliers (payment deferrals) - Risks and reputation
Large and especially overdue accounts payable may indicate financial difficulties. This can deter investors, partners, and lenders, and at a critical level of debt and lack of resources to repay it, bankruptcy proceedings may be initiated
Annual Accounts Payables ICON Public Limited Company
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 173 M | 132 M | 81.2 M | 90.8 M | 51.1 M | 24 M | 13.3 M | 18.6 M | 8.7 M | 7.02 M | 2.79 M | 4.59 M | 8.15 M | 5.34 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 173 M | 2.79 M | 44.3 M |
Quarterly Accounts Payables ICON Public Limited Company
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 63.5 M | 90.8 M | 62.6 M | 37.8 M | 48.1 M | 51.1 M | 28.7 M | 32.7 M | 23.3 M | 24 M | 20.8 M | 20.2 M | 19.3 M | 13.3 M | 15.3 M | 15.1 M | 11.8 M | 18.6 M | 13 M | 7.86 M | 13.6 M | 8.7 M | 5.05 M | 6.12 M | 5.65 M | 7.02 M | 4.53 M | 6.3 M | 3.86 M | 2.79 M | 5.91 M | 10.9 M | 6.66 M | 4.59 M | 8.85 M | 11.8 M | 6.79 M | 8.15 M | 9.33 M | 8.07 M | 5.49 M | 5.34 M | 6.52 M | 4.29 M | 8.61 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 90.8 M | 2.79 M | 17.6 M |
Accounts Payables of other stocks in the Diagnostics research industry
| Issuer | Accounts Payables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Akumin
AKU
|
36.6 M | - | -17.87 % | $ 25.9 M | ||
|
Anixa Biosciences
ANIX
|
165 K | $ 3.11 | -2.51 % | $ 101 K | ||
|
Accelerate Diagnostics
AXDX
|
4.5 M | - | -61.36 % | $ 2.46 M | ||
|
BioNano Genomics
BNGO
|
6.96 M | $ 1.45 | -3.67 % | $ 1.84 M | ||
|
Aspira Women's Health
AWH
|
881 K | - | -6.19 % | $ 10.5 M | ||
|
Burning Rock Biotech Limited
BNR
|
63.1 M | $ 30.5 | -4.72 % | $ 328 M | ||
|
Biocept
BIOC
|
1.52 M | - | -13.05 % | $ 7.29 M | ||
|
Check-Cap Ltd.
CHEK
|
952 K | - | - | $ 9.42 M | ||
|
Castle Biosciences
CSTL
|
6.9 M | $ 40.78 | 1.92 % | $ 1.13 B | ||
|
Co-Diagnostics
CODX
|
1.48 M | - | - | $ 79.8 M | ||
|
DexCom
DXCM
|
276 M | $ 70.44 | 1.29 % | $ 27.2 B | ||
|
Chembio Diagnostics
CEMI
|
3.34 M | - | 0.22 % | $ 16.8 M | ||
|
Guardant Health
GH
|
38.6 M | $ 113.62 | 1.32 % | $ 13.9 B | ||
|
Global Cord Blood Corporation
CO
|
8.33 M | - | - | $ 399 M | ||
|
DermTech
DMTK
|
1.48 M | - | -11.32 % | $ 2.94 M | ||
|
Illumina
ILMN
|
221 M | $ 147.36 | 4.03 % | $ 23.4 B | ||
|
CareDx, Inc
CDNA
|
12.9 M | $ 20.08 | 0.35 % | $ 1.08 B | ||
|
Danaher Corporation
DHR
|
1.75 B | $ 234.95 | -0.44 % | $ 172 B | ||
|
Celcuity
CELC
|
9.37 M | $ 105.63 | -1.25 % | $ 4.17 B | ||
|
DarioHealth Corp.
DRIO
|
1.13 M | $ 12.48 | 0.28 % | $ 354 M | ||
|
Enzo Biochem
ENZ
|
1.38 M | - | -8.98 % | $ 14.8 K | ||
|
Fulgent Genetics
FLGT
|
18.4 M | $ 27.65 | -1.53 % | $ 836 M | ||
|
HTG Molecular Diagnostics
HTGM
|
1.16 M | - | -20.0 % | $ 1.06 M | ||
|
Exact Sciences Corporation
EXAS
|
89.6 M | $ 102.21 | -0.22 % | $ 18.9 B | ||
|
Lantheus Holdings
LNTH
|
34.6 M | $ 66.02 | 2.75 % | $ 4.57 B | ||
|
Medpace Holdings
MEDP
|
32.5 M | $ 602.32 | -1.41 % | $ 18.6 B | ||
|
IQVIA Holdings
IQV
|
322 M | $ 234.18 | -1.47 % | $ 42.5 B | ||
|
QIAGEN N.V.
QGEN
|
83.3 M | - | - | $ 10.6 B | ||
|
Heska Corporation
HSKA
|
16.4 M | - | - | $ 1.31 B | ||
|
Neogen Corporation
NEOG
|
79.6 M | $ 9.28 | 0.27 % | $ 2.01 B | ||
|
National Research Corporation
NRC
|
1.3 M | $ 22.06 | -0.72 % | $ 541 M | ||
|
Charles River Laboratories International
CRL
|
140 M | $ 219.04 | -0.3 % | $ 11.3 B | ||
|
OPKO Health
OPK
|
47.1 M | $ 1.3 | 1.56 % | $ 902 M | ||
|
Pacific Biosciences of California
PACB
|
15.1 M | $ 2.36 | 6.79 % | $ 599 M | ||
|
Quest Diagnostics Incorporated
DGX
|
287 M | $ 188.87 | -0.33 % | $ 21 B | ||
|
Biodesix
BDSX
|
2.19 M | $ 8.85 | 12.25 % | $ 1.15 B | ||
|
Mettler-Toledo International
MTD
|
216 M | $ 1 409.56 | -3.5 % | $ 29.9 B | ||
|
Laboratory Corporation of America Holdings
LH
|
876 M | $ 272.02 | 0.42 % | $ 22.8 B | ||
|
IDEXX Laboratories
IDXX
|
114 M | $ 688.67 | -3.73 % | $ 56.8 B | ||
|
Myriad Genetics
MYGN
|
32.3 M | $ 5.65 | -4.56 % | $ 512 M | ||
|
ENDRA Life Sciences
NDRA
|
270 K | $ 4.67 | -2.3 % | $ 2.51 M | ||
|
Agilent Technologies
A
|
446 M | $ 135.52 | -2.95 % | $ 41.2 B |